Australia’s Vaping Reforms Are Already Being Declared a Success. The Science Says the Evidence Isn’t There Yet.

A newly published paper in Tobacco Control has been presented as providing the “first results” of Australia’s sweeping vaping reforms, with the authors reporting that vaping prevalence in South Australia declined in 2024 after peaking in 2023 and suggesting that this may indicate the country’s increasingly restrictive regulatory approach is beginning to achieve its intended objectives.

At first glance, the findings appear encouraging for proponents of prohibition. However, a careful examination of the study design and the available evidence suggests that the conclusions being drawn are considerably stronger than the data can support.

The study employs a repeated cross-sectional design, which is valuable for monitoring population trends over time but is inherently limited in its capacity to establish causation. Repeated cross-sectional surveys can identify temporal associations between events, but they cannot determine whether an observed change occurred because of a policy intervention or because of other contemporaneous factors. Unlike a randomised controlled trial or a robust natural experiment, this study lacks an appropriate counterfactual. There is no control group, no ability to isolate the effect of the reforms from other influences, and no mechanism through which causal inferences can be made with confidence.

This distinction is critical because the Australian nicotine market experienced extraordinary disruption during the study period. The reforms did not occur in isolation. They were accompanied by intensified enforcement activities, import restrictions, substantial changes to product availability, extensive media coverage, changes in retail access, and rapid adaptation of illicit supply chains. Consumer behaviour was therefore influenced by a complex and evolving environment in which multiple factors were acting simultaneously.

In epidemiological terms, the study is highly susceptible to confounding. Any of these concurrent factors could plausibly explain some or all of the observed decline in vaping prevalence. Reduced product availability may have temporarily suppressed use, increased prices may have altered purchasing behaviour, media attention may have influenced social desirability bias in self-reporting, and uncertainty surrounding the regulatory environment may have encouraged some users to temporarily abstain or underreport their consumption. Without adequately accounting for these potential confounders, attributing the decline principally to the legislative changes is speculative rather than evidential.

The issue of temporality further weakens any causal interpretation. The authors are attempting to evaluate one of the most significant nicotine policy interventions in Australian history after only a very short follow-up period. Behavioural responses to major regulatory interventions frequently evolve over several years rather than several months. Initial effects often differ substantially from long-term outcomes because consumers and markets adapt over time. Short-term declines following regulatory disruption may represent transient responses rather than durable behavioural change.

The history of public health interventions is replete with examples in which early outcomes failed to predict longer-term consequences. Declaring success on the basis of a single year of post-implementation data, therefore, risks confusing short-term market disruption with sustained population-level benefit.

There are also substantial concerns regarding external validity. The study relies exclusively on data from South Australia, yet its findings are likely to be interpreted as evidence supporting Australia’s national policy framework. Such extrapolation is problematic because substantial heterogeneity exists across Australian jurisdictions. Patterns of enforcement differ between states, the size and structure of illicit markets vary considerably, and consumer behaviours are not uniform across the country. Consequently, findings from a single state cannot reasonably be assumed to reflect the experiences of the entire nation.

The interpretation of changes among younger age groups also warrants caution. The paper highlights large relative changes in vaping prevalence among adolescents and young adults, but percentage changes can be misleading when derived from relatively small subgroup populations. Estimates based on small numbers are inherently more volatile and are accompanied by wider confidence intervals, meaning that relatively modest changes in absolute numbers can generate apparently dramatic shifts in prevalence estimates. Such findings should therefore be interpreted conservatively and within the context of statistical uncertainty.

Perhaps the most significant limitation of the study, however, lies not in what it measures but in what it fails to measure.

The primary public health objective of tobacco and nicotine policy is not simply to reduce vaping prevalence. It is to reduce smoking-related disease, premature mortality, and overall population harm. Yet the paper provides no meaningful assessment of smoking behaviour following the reforms. There is no examination of whether smokers returned to combustible tobacco, no assessment of whether smoking prevalence changed among former vapers, and little consideration of whether unintended adverse consequences may have accompanied reductions in vaping.

This omission is particularly important because nicotine products exist within an interconnected behavioural ecosystem. Changes in the availability or attractiveness of one product can influence the consumption patterns of another. If reduced access to vaping products leads some individuals to initiate smoking, relapse to smoking, or delay smoking cessation, then reductions in vaping prevalence alone cannot be interpreted as a public health success.

Indeed, this possibility becomes increasingly relevant when Australia’s experience is considered alongside developments in New Zealand. While Australia has adopted one of the world’s most restrictive approaches to vaping regulation, New Zealand maintained regulated adult access to nicotine vaping products while simultaneously continuing its comprehensive tobacco control strategies. The result has been one of the most rapid declines in smoking prevalence ever recorded in New Zealand.

By contrast, Australia’s long-term decline in smoking appears to have slowed and, in certain demographic groups, smoking prevalence has increased. Although ecological comparisons between countries cannot establish causality, these divergent trajectories raise important questions regarding the potential role of vaping as a substitute for smoking and suggest that Australia’s regulatory approach should be subjected to rigorous scrutiny rather than premature celebration.

The study undoubtedly contributes valuable surveillance data, and there is merit in documenting early changes in vaping prevalence. However, surveillance data should not be conflated with evidence of policy effectiveness. The findings demonstrate only that vaping prevalence in one Australian state declined following a period of rapid growth and major regulatory disruption.

They do not establish that the reforms caused the decline.

They do not demonstrate that smoking-related harm has been reduced.

They do not show that overall public health has improved.

And they certainly do not justify definitive claims that Australia’s vaping reforms have been successful.

Scientific integrity requires that major policy interventions be evaluated cautiously, comprehensively, and over sufficiently long time horizons to capture both intended and unintended consequences. At present, the available evidence does not permit the conclusion that Australia’s vaping reforms have achieved their stated public health objectives.

The only scientifically defensible conclusion is that an association has been observed between the implementation of the reforms and a subsequent decline in vaping prevalence in South Australia. Whether that association is causal, whether it will persist, and whether it ultimately translates into improved public health outcomes remain entirely open questions.